Alliance Global analyst Matthew Venezia raised the firm’s price target on Medicus Pharma (MDCX) to $1 from 90c and keeps a Buy rating on the shares following a transfer of coverage.
The firm cites the the addition of CD228V to the company for the target boost. Medicus recently in-licensed CD228V, an engineered antibody drug conjugate indicated for a range of solid tumors, the analyst tells investors in a research note. SOURCE: TipRanks.com
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was inco… [Read more]
IndustryDrug Manufacturers – General
SectorHealthcare
Founded2008
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolMDCX
Websitehttps://medicuspharma.com